Respinova has developed a novel non-invasive technology, PulseHaler, that aims to treat the core of COPD pathophysiology. COPD is projected to be the world’s 3rd leading cause of death by 2020, affecting 5-10% of the population. We are also applying our technology to improve the delivery of inhaled drugs.
Company’s Keywords:
<3
<
<2008